In sum, these data suggest that Ras pathway and cell cycle regulators regulate selumetinib responses in NF1-mutant, PRC2-intact neurofibroma cells, while tumor suppressor genes and genes affecting cell differentiation may underlie more general growth responses as well as selumetinib responses. Here, NF1 is linked to neurofibroma.